Critique of closure or medical therapy for cryptogenic stroke with patent foramen ovale: The hole truth?

Stroke

Volumn 43, Issue 11, 2012, Pages 3147-3149

  Thaler, David E ^a   Wahl, Andreas ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

endovascular treatment; patent foramen ovale; prevention; stroke; young adults

Indexed keywords

ARTICLE; CARDIAC EQUIPMENT; CEREBROVASCULAR ACCIDENT; ENDOVASCULAR SURGERY; HUMAN; MEDICAL ERROR; PATENT FORAMEN OVALE; PRIORITY JOURNAL; SEPTAL OCCLUDER; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

FORAMEN OVALE, PATENT; HUMANS; STROKE;

EID: 84868194049     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.659599     Document Type: Article

References (22)

1. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled tri-als. BMJ. 2003;327:1459-1461.
2. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991-999.
3. Huxley T. Biogenesis and abiogenesis. Collected essays. Volume 8. New York, NY: Greenwood Press. 1870; 22.
4. Messe SR, Cucchiara B, Luciano J, Kasner SE. PFO management: neurolo-gists vs cardiologists. Neurology. 2005;65:172-173.
5. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in crypto-genic stroke: incidental or pathogenic? Stroke. 2009;40:2349-2355.
6. Kent DM, Thaler DE, RoPE Study Investigators. The Risk of Paradoxical Embolism (RoPE) Study: developing risk models for application to ongo-ing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. Trials. 2011;12:185.
7. Kent DM, Ruthazer R, Weimar C, Serena J, Mas JL, Homma S, et al. An index to identify cryptogenic stroke patients whose stroke is likely attrib-utable to patent foramen ovale [Abstract]. Presented at the International Stroke Conference, New Orleans, LA. Feb 1, 2012.
8. Wahl A, Tai T, Praz F, Schwerzmann M, Seiler C, Nedeltchev K, et al. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size. J Am Coll Cardiol Cardiovasc Interv. 2009;2:116-123.
9. Bonvini RF, Sztajzel R, Dorsaz PA, Righini M, Bonvin C, Alibegovic J, et al. Incidence of atrial fibrillation after percutaneous closure of patent foramen ovale and small atrial septal defects in patients presenting with cryptogenic stroke. Int J Stroke. 2010;5:4-9.
10. Krumsdorf U, Ostermayer S, Billinger K, Trepels T, Zadan E, Horvath K, et al. Incidence and clinical course of thrombus formation on atrial sep-tal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. 2004;43:302-309.
11. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent foramen ovale closure and medical treatments for secondary stroke pre-vention: a systematic review of observational and randomized evidence. Stroke. 2012;43:422-431.
12. Wahl A, Juni P, Mono ML, Kalesan B, Praz F, Geister L, et al. Long-term propensity score-matched comparison of percutaneous closure of pat-ent foramen ovale with medical treatment after paradoxical embolism. Circulation. 2012;125:803-812.
13. Khattab AA, Windecker S, Juni P, Hildick-Smith D, Dudek D, Andersen HR, et al. Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with med-ical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design. Trials. 2011;12:56.
14. Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care treatment. Clinicaltrials.gov registry website. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00465 270?term=Randomized+Evaluation+of+Recurrent+Stroke+Comparing+ PFO+Closure+to+Established+Current+Standard+of+Care+Treatment.& rank=1. Accessed May 15, 2012.
15. GORE HELEX septal occluder for patent foramen ovale (PFO) closure in stroke patients-The Gore REDUCE Clinical Study (HLX 06-03). Clinicaltrials. gov registry website. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00738894?term=GORE+HELEX%E2%84%A2+Septal+ Occluder+for+Patent+Foramen+Ovale+%28PFO%29+Closure+in+Str oke+Patients+- +The+Gore+REDUCE+Clinical+Study+%28HLX+06-03%29&rank=1. Accessed May 15, 2012.
16. Patent foramen ovale closure or anticoagulants versus antiplatelet therapy to prevent stroke recurrence (CLOSE). Clinicaltrials.gov registry website. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00562289?ter m=Patent+Foramen+Ovale+Closure+or+Anticoagulants+Versus+Antip latelet+Therapy+to+Prevent+Stroke+Recurrence+%28CLOSE%29+.&r ank=1. Accessed May 15, 2012.
17. Kennedy J, Quan H, Ghali WA, Feasby TE. Variations in rates of appropri-ate and inappropriate carotid endarterectomy for stroke prevention in 4 Canadian provinces. CMAJ. 2004;171:455-459.
18. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298:1209-1212.
19. For patients: Patients with PFO. PFO Research Foundation website. Available at: http://pforesearch.org/?q=patients/patients-pfo. Accessed May 15, 2012.
20. Patient-centered outcomes research institute. Patient-centered outcomes research website. Available at: http://www.pcori.org. Accessed May 15, 2012.
21. Husten L. Study closes the book on PFO closure. CardioBrief website. Published November, 15, 2010. Available at: http://cardiobrief.org/2010/11/15/ study-closes-the-book-on-pfo-closure/. Accessed May 15, 2012.
22. Huxley T. Elementary instruction in physiology. In: Science and culture, and other essays.New York, NY: D Appleton and Company. 1882; p. 94.